KR101351515B1 - 방사성 핵종이 표지되고 약물이 담지된 고분자 하이드로겔 및 이의 제조방법, 및 이를 유효성분으로 함유하는 암 치료용 약학 조성물 - Google Patents

방사성 핵종이 표지되고 약물이 담지된 고분자 하이드로겔 및 이의 제조방법, 및 이를 유효성분으로 함유하는 암 치료용 약학 조성물 Download PDF

Info

Publication number
KR101351515B1
KR101351515B1 KR1020110096205A KR20110096205A KR101351515B1 KR 101351515 B1 KR101351515 B1 KR 101351515B1 KR 1020110096205 A KR1020110096205 A KR 1020110096205A KR 20110096205 A KR20110096205 A KR 20110096205A KR 101351515 B1 KR101351515 B1 KR 101351515B1
Authority
KR
South Korea
Prior art keywords
shpp
chitosan
cancer
labeled
hydrogel
Prior art date
Application number
KR1020110096205A
Other languages
English (en)
Korean (ko)
Other versions
KR20130032547A (ko
Inventor
이창문
정환정
임석태
손명희
Original Assignee
전북대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 전북대학교산학협력단 filed Critical 전북대학교산학협력단
Priority to KR1020110096205A priority Critical patent/KR101351515B1/ko
Priority to PCT/KR2011/010344 priority patent/WO2013042834A1/fr
Publication of KR20130032547A publication Critical patent/KR20130032547A/ko
Application granted granted Critical
Publication of KR101351515B1 publication Critical patent/KR101351515B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1213—Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020110096205A 2011-09-23 2011-09-23 방사성 핵종이 표지되고 약물이 담지된 고분자 하이드로겔 및 이의 제조방법, 및 이를 유효성분으로 함유하는 암 치료용 약학 조성물 KR101351515B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020110096205A KR101351515B1 (ko) 2011-09-23 2011-09-23 방사성 핵종이 표지되고 약물이 담지된 고분자 하이드로겔 및 이의 제조방법, 및 이를 유효성분으로 함유하는 암 치료용 약학 조성물
PCT/KR2011/010344 WO2013042834A1 (fr) 2011-09-23 2011-12-29 Hydrogel polymère marqué par radionucléide et portant un médicament et procédé de production associé, et composition pharmaceutique permettant de traiter le cancer le comprenant comme principe actif

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020110096205A KR101351515B1 (ko) 2011-09-23 2011-09-23 방사성 핵종이 표지되고 약물이 담지된 고분자 하이드로겔 및 이의 제조방법, 및 이를 유효성분으로 함유하는 암 치료용 약학 조성물

Publications (2)

Publication Number Publication Date
KR20130032547A KR20130032547A (ko) 2013-04-02
KR101351515B1 true KR101351515B1 (ko) 2014-01-15

Family

ID=47914575

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020110096205A KR101351515B1 (ko) 2011-09-23 2011-09-23 방사성 핵종이 표지되고 약물이 담지된 고분자 하이드로겔 및 이의 제조방법, 및 이를 유효성분으로 함유하는 암 치료용 약학 조성물

Country Status (2)

Country Link
KR (1) KR101351515B1 (fr)
WO (1) WO2013042834A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2756621C1 (ru) * 2019-11-29 2021-10-04 Ион Бим Аппликейшнз Способ получения ас-225 из ra-226

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015156426A1 (fr) * 2014-04-07 2015-10-15 전북대학교 산학협력단 Hydrogel polymere marque par un radionucleide et chargeant une proteine ou un peptide activant l'angiogenese, procede de preparation correspondant et composition pharmaceutique contenant cet hydrogel en tant que principe actif et destinee a prevenir ou a traiter une maladie ischemique
KR20170017522A (ko) * 2015-08-07 2017-02-15 전북대학교산학협력단 암 치료를 위한 키토산-킬레이터 하이드로겔 및 이의 제조방법, 및 이를 유효성분으로 함유하는 약학적 조성물 및 색전 치료용 조성물
KR101670249B1 (ko) * 2016-02-16 2016-10-31 (주) 메디프레소 항암제 약물전달체 및 이의 제조방법
KR20220123260A (ko) * 2020-01-30 2022-09-06 (주)카이바이오텍 암 치료를 위한 키토산 하이드로겔-킬레이터의 제조방법
KR20240050074A (ko) 2022-10-11 2024-04-18 충북대학교 산학협력단 젬시타빈 및 라파마이신이 봉입된 온도민감성 plga-peg-plga 하이드로겔 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352682B2 (en) 1996-03-11 2002-03-05 Focal, Inc. Polymeric delivery of radionuclides and radiopharmaceuticals
KR20050020814A (ko) * 1996-03-12 2005-03-04 피지-티엑스엘 컴파니,엘.피. 수용성 파클리탁셀 전구약물을 포함하는 조성물 및 이러한조성물을 포함하는 이식가능한 의료장치
KR100530276B1 (ko) 1998-10-12 2006-02-28 서울대학교병원 입자성 방사성핵종 포합 중합체, 그 제조방법 및 그 제조용킷트
KR20060060970A (ko) * 2004-12-01 2006-06-07 동화약품공업주식회사 체내 주사시 겔화 안정성이 개선된 방사성물질-키토산복합체용액 조성물 및 그 제조 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2522575T3 (es) * 2003-10-22 2014-11-17 Encelle, Inc. Composiciones de hidrogel bioactivo para la regeneración del tejido conjuntivo
KR100918524B1 (ko) * 2007-02-14 2009-09-21 성균관대학교산학협력단 온도 및 피에치 민감성 블록공중합체 고분자 하이드로겔을이용한 주사가능한 약물전달체 및 약물전달방법
KR20090002946A (ko) * 2007-07-05 2009-01-09 한국산업기술평가원(관리부서:요업기술원) 상호침투성 가교구조를 갖는 온도감응성 고분자하이드로겔, 이의 제조방법 및 이를 포함하는 주사제형약물전달체

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352682B2 (en) 1996-03-11 2002-03-05 Focal, Inc. Polymeric delivery of radionuclides and radiopharmaceuticals
KR20050020814A (ko) * 1996-03-12 2005-03-04 피지-티엑스엘 컴파니,엘.피. 수용성 파클리탁셀 전구약물을 포함하는 조성물 및 이러한조성물을 포함하는 이식가능한 의료장치
KR100530276B1 (ko) 1998-10-12 2006-02-28 서울대학교병원 입자성 방사성핵종 포합 중합체, 그 제조방법 및 그 제조용킷트
KR20060060970A (ko) * 2004-12-01 2006-06-07 동화약품공업주식회사 체내 주사시 겔화 안정성이 개선된 방사성물질-키토산복합체용액 조성물 및 그 제조 방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2756621C1 (ru) * 2019-11-29 2021-10-04 Ион Бим Аппликейшнз Способ получения ас-225 из ra-226

Also Published As

Publication number Publication date
WO2013042834A1 (fr) 2013-03-28
KR20130032547A (ko) 2013-04-02

Similar Documents

Publication Publication Date Title
KR101351515B1 (ko) 방사성 핵종이 표지되고 약물이 담지된 고분자 하이드로겔 및 이의 제조방법, 및 이를 유효성분으로 함유하는 암 치료용 약학 조성물
Wu et al. Injectable magnetic supramolecular hydrogel with magnetocaloric liquid-conformal property prevents post-operative recurrence in a breast cancer model
Yang et al. In vivo targeting of metastatic breast cancer via tumor vasculature-specific nano-graphene oxide
CA2577589C (fr) Microcapsules d'alginate de sodium contenant du paclitaxel qui permet de traiter un embole vasculaire
Seo et al. Self-assembled 20-nm 64Cu-micelles enhance accumulation in rat glioblastoma
Yang et al. A positron emission tomography image-guidable unimolecular micelle nanoplatform for cancer theranostic applications
JP2020502130A5 (fr)
CN102573613B (zh) 用于增强肿瘤显像的paa纳米粒子
Shih et al. EGFR-targeted micelles containing near-infrared dye for enhanced photothermal therapy in colorectal cancer
CN105520906B (zh) 一种载有盐酸阿霉素的温敏自愈水凝胶及其制备方法
US10548996B2 (en) Hydrogels for localized radiotherapy
Chen et al. Paclitaxel loaded phospholipid-based gel as a drug delivery system for local treatment of glioma
KR101630251B1 (ko) 가용화된 광감작제를 유효성분으로 하는 진단 또는 치료용 약학적 조성물
EP2978420A1 (fr) Nanocomposition stable comprenant du paclitaxel, procédé pour sa préparation, son utilisation et compositions pharmaceutiques la contenant
Shi et al. Copper (II)-disulfiram loaded melanin-dots for cancer theranostics
CN110664753A (zh) 一种负载抗癌药物骨靶向低氧响应纳米胶束及其制备方法
Wang et al. Downshifting nanoprobes with follicle stimulating hormone peptide fabrication for highly efficient NIR II fluorescent bioimaging guided ovarian tumor surgery
KR20170017522A (ko) 암 치료를 위한 키토산-킬레이터 하이드로겔 및 이의 제조방법, 및 이를 유효성분으로 함유하는 약학적 조성물 및 색전 치료용 조성물
EP2745850B1 (fr) Nanoparticules pour radiothérapie interne d'une zone concernée et système de thérapie
JP2014105161A (ja) 金属イオン含有両親媒性ブロックポリマー及び金属イオン含有ナノ粒子、並びに前記ナノ粒子を用いた分子イメージング用プローブ及び薬剤搬送システム
Ribeiro et al. Docetaxel-loaded block copolymer micelles labeled with 188Re for combined radiochemotherapy
CN114452256A (zh) 脊髓损伤靶向药物、聚合物-疏水化合物胶束及其制备方法
KR101481447B1 (ko) 방사성 핵종이 표지되고 혈관신생-촉진 단백질 또는 펩티드가, 담지된 고분자 하이드로겔, 이의 제조 방법 및 이를 유효성분으로 포함하는 허혈성 질환의 예방 또는 치료용 약학 조성물
CN101401792B (zh) 一种纳米囊及纳米囊复合微球的制备方法
Banzato et al. Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20170106

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20180108

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20190131

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20200108

Year of fee payment: 7